Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Matt Hancock says vaccine rollout will be ‘one of the biggest civilian logistical efforts nation has faced’

Health secretary says conference centres and sports halls will be used to administer jabs

Ashley Cowburn
Political Correspondent
Wednesday 02 December 2020 20:29 GMT
Comments
Covid-19 jab approved in UK with vaccination to start next week

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Matt Hancock has said the rollout of the newly-approved Covid-19 vaccine will be “one of the biggest civilian logistical effort we’ve faced as a nation”, with conference centres and sports halls being used to administer jabs.

The health secretary added that an initial batch of 800,000 vaccines had been tested on Wednesday and will be ready for deployment by the NHS early next week.

It comes after the UK’s independent medicines agency approved a vaccine developed by Pfizer/BioNTech in a move that was heralded as a landmark moment in the fight against coronavirus.

The government is also awaiting the verdict of the Medicines and Healthcare products Regulatory Agency (MHRA) on a second vaccine produced by the University of Oxford and AstraZeneca, with 100 million doses on order.

Describing the news as “a day to remember in a year to forget”, Mr Hancock outlined how the vaccine will be delivered in three different ways, beginning in hospital hubs, then through GPs, local community services and pharmacies.

“Third, we’ll stand up vaccination centres in conference centres and sports venues, for example, to vaccinate large numbers of people as more vaccines come on stream,” he said.

In a Commons statement, the cabinet minister added: “It will be difficult. There will be challenges and complications, but I know that the NHS is equal to the task.

“We will deliver according to clinical prioritisation and operational necessity because of the need to hold the vaccine at minus-70 it makes this vaccine particularly challenging to deploy.”

He went on: “We’ve spent months preparing for this day so that as soon as we get the green light we would be ready to go.

“We are the first country in the world to pre-order supplies of this successful vaccine and we have 40 million doses pre-ordered for delivering over the coming months, enough for 20 million people because two jabs are required for each.

“Following authorisation, the next stage is to test each batch of the vaccine for safety and I can confirm that batch testing has been completed this morning for the first deployment of 800,000 doses of the vaccine.”

However, Mr Hancock was unable to tell MPs how many individuals would need to be vaccinated before measures that have restricted people’s lives since the onset of the pandemic in March could be lifted.

Pressed by the shadow health secretary Jonathan Ashworth, he replied: “Of course I understand that not only why he but almost everybody else in the country wants to know the answer to this question – how many people do you have to vaccinate before you can start lifting restrictions?

“The answer to that is while we know that the vaccine protects you as an individual with a 95 per cent efficacy, we do not know the impact of the vaccine on reducing the transmission because of the problem of asymptomatic transmission – which has so bedevilled our response to this virus and made it so hard to tackle. Therefore we don’t know the answer to that question.”

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in